Canopy Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.14M Buy
1,784
+16
+0.9% +$16.3K 0.64% 31
2026
Q1
$1.63M Sell
1,768
-40
-2% -$40.6K 0.56% 35
2025
Q4
$1.94M Buy
1,808
+56
+3% +$53.5K 0.63% 34
2025
Q3
$1.34M Buy
1,752
+196
+13% +$146K 0.45% 46
2025
Q2
$1.21M Buy
1,556
+428
+38% +$333K 0.44% 48
2025
Q1
$932K Buy
1,128
+37
+3% +$30.8K 0.36% 64
2024
Q4
$842K Buy
1,091
+4
+0.4% +$3.31K 0.32% 68
2024
Q3
$963K Sell
1,087
-13
-1% -$11.7K 0.41% 53
2024
Q2
$996K Buy
1,100
+13
+1% +$10.4K 0.46% 42
2024
Q1
$846K Buy
1,087
+295
+37% +$210K 0.41% 54
2023
Q4
$462K Buy
+792
New +$462K 0.28% 84

Other funds holding LLY

Canopy Partners's LLY Position: Q2 2026 in Review

Canopy Partners increased its Eli Lilly (LLY) stake by 0.9% in Q2 2026, buying an estimated $16.3K and bringing the position to 1,784 shares worth $2.14M. The position accounts for 0.64% of the portfolio, ranked #31.

Canopy Partners first reported a position in LLY in Q4 2023 and has held it in 11 quarters since. 1,537 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Canopy Partners held 1,784 shares of Eli Lilly worth $2.14M as of Q2 2026.
  • Canopy Partners bought 16 Eli Lilly shares in Q2 2026, an estimated $16.3K.
  • Eli Lilly made up 0.64% of Canopy Partners's portfolio in Q2 2026, its #31 holding.
  • Canopy Partners first reported a position in Eli Lilly in Q4 2023 and has held it in 11 quarters since.
  • 1,537 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Canopy Partners's 13F filing for Q2 2026, filed 22 Jul 2026.